×
About 9,743 results

A Prospective Population-Based Study of Cardiovascular Disease Mortality following Trea...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857851
Current Oncology (Toronto, Ont.); Appiah D, Mai M et. al.

Jan 21st, 2023 - Male breast cancer is rare but its incidence and mortality are increasing in the United States, with racial/ethnic disparities in survival reported. There is limited evidence for cardiotoxicity of cancer treatment among men with breast cancer. We evaluated the relation between breast cancer treatment and cardiovascular disease (CVD) mortality among men and investigated the salient roles that ra...

Ancestral risk modification for multiple sclerosis susceptibility detected across the M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778564
PloS One; Beecham AH, Amezcua L et. al.

Dec 23rd, 2022 - The Major Histocompatibility Complex (MHC) makes the largest genetic contribution to multiple sclerosis (MS) susceptibility, with 32 independent effects across the region explaining 20% of the heritability in European populations. Variation is high across populations with allele frequency differences and population-specific risk alleles identified. We sought to identify MHC-specific MS suscepti...

Evolution of immune genes is associated with the Black Death.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580435
Nature Klunk J, Vilgalys TP et. al.

Oct 20th, 2022 - Infectious diseases are among the strongest selective pressures driving human evolution1,2. This includes the single greatest mortality event in recorded history, the first outbreak of the second pandemic of plague, commonly called the Black Death, which was caused by the bacterium Yersinia pestis3. This pandemic devastated Afro-Eurasia, killing up to 30-50% of the population4. To identify loci...

In-silico study of influence of HLA heterogeneity on CTL responses across ethnicities t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550298
Human Immunology; Rao V, Chandra N

Oct 14th, 2022 - Differences in outcome to COVID-19 infection in different individuals is largely attributed to genetic heterogeneity leading to differential immune responses across individuals and populations. HLA is one such genetic factor that varies across individuals leading to differences in how T-cell responses are triggered against SARS-CoV-2, directly influencing disease susceptibility. HLA alleles tha...

Burden of lymphedema in long-term breast cancer survivors by race and age.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879608
Cancer Ren Y, Kebede MA et. al.

Oct 13th, 2022 - Risk assessment for breast cancer-related lymphedema has emphasized upper-limb symptoms and treatment-related risk factors. This article examined breast cancer-related lymphedema after surgery, overall and in association with broader demographic and clinical features. The Carolina Breast Cancer Study phase 3 followed participants for breast cancer-related lymphedema from baseline (on average, 5...

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bi...
https://doi.org/10.1001/jamanetworkopen.2022.28877
JAMA Network Open; Alqazaqi R, Schinke C et. al.

Aug 27th, 2022 - The use of chimeric antigen receptor-T cell (CAR-T) therapy and bispecific antibodies in multiple myeloma is expanding, with encouraging early results. It is unknown if the current geographic distribution of CAR-T therapy and bispecific antibodies in multiple myeloma allows access for patients in need, especially for Black populations, which have a higher incidence of multiple myeloma. To inves...

CFTR genotype analysis of Asians in international registries highlights disparities in ...
https://doi.org/10.1016/j.gim.2022.06.009
Genetics in Medicine : Official Journal of the American C... Vaidyanathan S, Trumbull AM et. al.

Jul 21st, 2022 - Cystic fibrosis (CF) is not well-characterized in Asians, potentially resulting in delayed diagnosis and poor prognosis. We characterized CF in Asian subgroups to address these disparities. De-identified ethnicity and CFTR variant data were obtained from the United States, United Kingdom, and Canadian CF registries. We measured the prevalence of CF, CFTR variant allele frequencies, effectivenes...

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327550
Blood Advances; Muffly L, Yin J et. al.

Jul 16th, 2022 - In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival data on AYAs enrolled on CALGB 10403 (N = 295, 2007-2012). Surveillance, Epidemiology, and End R...

High early death rates, treatment resistance, and short survival of Black adolescents a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577622
Blood Advances; Larkin KT, Nicolet D et. al.

Jul 6th, 2022 - Survival of patients with acute myeloid leukemia (AML) is inversely associated with age, but the impact of race on outcomes of adolescent and young adult (AYA; range, 18-39 years) patients is unknown. We compared survival of 89 non-Hispanic Black and 566 non-Hispanic White AYA patients with AML treated on frontline Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology protocols. ...

Trends in Cancer Mortality Among Black Individuals in the US From 1999 to 2019.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121301
JAMA Oncology; Lawrence WR, McGee-Avila JK et. al.

May 20th, 2022 - Cancer is the second leading cause of mortality in the US. Despite national decreases in cancer mortality, Black individuals continue to have the highest cancer death rates. To examine national trends in cancer mortality from 1999 to 2019 among Black individuals by demographic characteristics and to compare cancer death rates in 2019 among Black individuals with rates in other racial and ethnic...

Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037582
Journal of General Internal Medicine; Wu EL, Kumar RN et. al.

Apr 27th, 2022 - Disparities in access to anti-SARS-CoV-2 monoclonal antibodies have not been well characterized. We sought to explore the impact of race/ethnicity as a social construct on monoclonal antibody delivery. Following implementation of a centralized infusion program at a large academic healthcare system, we reviewed a random sample of high-risk ambulatory adult patients with COVID-19 referred for mon...

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021907
JAMA Network Open; Al Hadidi S, Schinke C et. al.

Apr 21st, 2022 - Disparities that affect Black persons with various hematological malignant neoplasms are substantial, yet little is known about disparities related to the use of US Food and Drug Administration (FDA)-approved chimeric antigen receptor-T cell (CAR-T) therapy. To examine the enrollment of Black participants in clinical trials that resulted in a subsequent FDA approval of CAR-T products in hematol...

Research in the USA on COVID-19's long-term effects: measures needed to ensure black, i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983399
Journal of Medical Ethics; Medeiros M, Edwards HA et. al.

Apr 3rd, 2022 - The SARS-CoV-2 (COVID-19) pandemic continues to expose underlying inequities in healthcare for black, indigenous and Latinx communities in the USA. The gaps in equitable care for communities of colour transcend the diagnosis, treatment and vaccinations related to COVID-19. We are experiencing a continued gap across racial and socioeconomic lines for those who suffer prolonged effects of COVID-1...

COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron V...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956338
MMWR. Morbidity and Mortality Weekly Report; Taylor CA, Whitaker M et. al.

Mar 25th, 2022 - Beginning the week of December 19-25, 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant in the United States (i.e., accounted for >50% of sequenced isolates).* Information on the impact that booster or additional doses of COVID-19 vaccines have on preventing hospitalizations during Omicron predominance is limited. Dat...

Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Pa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273372
Journal of Clinical Oncology : Official Journal of the Am... Riner AN, Girma S et. al.

Mar 23rd, 2022 - Clinical trials determine safety and efficacy of cancer therapeutics and establish standards of care. Minority patient participation in cancer clinical trials is dismal. We aimed to determine the impact of eligibility criteria on disparities in pancreatic ductal adenocarcinoma (PDAC) clinical trial candidacy. Traditional PDAC trial eligibility criteria were obtained from ClinicalTrials.gov. Pat...

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
https://doi.org/10.1056/NEJMoa2106535
The New England Journal of Medicine; Merrill JT, Werth VP et. al.

Mar 17th, 2022 - Iberdomide, a cereblon modulator promoting degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity, is being evaluated for the treatment of systemic lupus erythematosus (SLE). In this phase 2 trial, we randomly assigned patients in a 2:2:1:2 ratio to receive oral iberdomide (at a dose of 0.45, 0.30, or 0.15 mg) or placebo once daily for 24...

Hospitalizations and Mortality From Non-SARS-CoV-2 Causes Among Medicare Beneficiaries ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908076
JAMA Network Open; Dang A, Thakker R et. al.

Mar 10th, 2022 - The increased hospital mortality rates from non-SARS-CoV-2 causes during the SARS-CoV-2 pandemic are incompletely characterized. To describe changes in mortality rates after hospitalization for non-SARS-CoV-2 conditions during the COVID-19 pandemic and how mortality varies by characteristics of the admission and hospital. Retrospective cohort study from January 2019 through September 2021 using...

Tumor molecular differences associated with outcome disparities of Black patients with ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047510
Head & Neck; Kim HAJ, Zeng PYF et. al.

Feb 22nd, 2022 - Numerous studies of head and neck squamous cell carcinoma (HNSCC) have demonstrated disparate outcomes by race and ethnicity. Beyond known associations with socioeconomic variables, whether these are also associated with differences in tumor molecular composition has thus far been poorly explored. We downloaded clinical and multiplatform molecular data from The Cancer Genome Atlas and other pub...

The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855595
BMC Cancer; Yang Y, Ding Y et. al.

Feb 20th, 2022 - Pancreatic ductal adenocarcinoma (PDAC) is the major subtype of pancreatic cancer and head PDACs show distinct characteristics from body/tail PDACs. With limited studies based on Asian population, the mutational landscape of Asian PDAC remains unclear. One hundred fifty-one Chinese patients with head PDAC were selected and underwent targeted 425-gene sequencing. Genomic alterations, tumor mutat...

Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolle...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844998
JAMA Network Open; Stewart J, Krows ML et. al.

Feb 15th, 2022 - Racial and ethnic diversity among study participants is associated with improved generalizability of clinical trial results and may address inequities in evidence that informs public health strategies. Novel strategies are needed for equitable access and recruitment of diverse clinical trial populations. To investigate demographic and geographical location data for participants in 2 remote COVI...